The Tobacco Bill currently being debated in Kenya has sparked intense discussion, with a key point of contention being its approach to nicotine products. The bill refers to all nicotine products, including cigarettes, vapes, and oral nicotine pouches, as "tobacco products" - despite the fact that some may contain no tobacco at all. This has raised concerns among scientists, who argue that such an approach fails to acknowledge the significant differences in risk between these products.
The science behind nicotine products is complex, and it's clear that not all products are created equal. Cigarettes, for example, contain thousands of chemicals, many of which are toxic and carcinogenic, due to the combustion process involved in smoking. In contrast, smoke-free nicotine products, such as vapes and nicotine pouches, avoid this combustion process and therefore expose users to fewer toxicants. While these products are not entirely harmless, the risk they pose is significantly lower than that of cigarettes.
Research has shown that smoke-free nicotine products can be effective tools for quitting smoking. A Cochrane living systematic review, updated in August, found high-certainty evidence that nicotine vapes increase quit rates compared with conventional nicotine replacement therapy. Additionally, the US Food and Drug Administration (FDA) has authorised 20 nicotine pouch products to carry a modified-risk claim, allowing consumers to be informed that switching from cigarettes to these products lowers the risk of several serious smoking-related diseases.
The debate around flavours in nicotine products has also been contentious. While some argue that flavours are used to appeal to children, research suggests that they can also play a crucial role in helping adults quit smoking. A study by Yale University researchers found that adults using flavoured products are twice as likely to quit cigarettes than those using tobacco flavours. The challenge for regulators is to balance the need to prevent youth access with the need to allow adults to access products that may help them quit smoking.
The Harm Reduction Society of Kenya has called for a nuanced approach to regulation, one that acknowledges the differences in risk between nicotine products. According to the Society's secretary-general, the goal is not to promote nicotine products, but to encourage adults who continue to smoke to move to alternatives that expose them to fewer toxicants. This approach prioritises public health while also recognising that abstinence is not always achievable.
As Kenya considers its Tobacco Control (Amendment) Bill, the scientific evidence suggests that a nuanced approach is necessary. Regulation can acknowledge that cigarettes, vapes, and nicotine pouches are not risk-free while also recognising that they are not equally harmful. By accurately communicating these distinctions and reflecting the strength, limitations, and direction of the evidence, policymakers can develop a bill that prioritises public health.
Ultimately, the goal of the Tobacco Bill should be to promote public health, and the science suggests that this can be achieved through a nuanced approach to regulation. By acknowledging the differences in risk between nicotine products and prioritising harm reduction, Kenya can develop a bill that protects the health of its citizens while also recognising the complexities of nicotine product regulation.
Key points
- The Tobacco Bill's approach to nicotine products as a single category has raised concerns among scientists, who argue that it fails to acknowledge the significant differences in risk between these products.
- Research has shown that smoke-free nicotine products can be effective tools for quitting smoking, with a Cochrane review finding high-certainty evidence that nicotine vapes increase quit rates.
- A nuanced approach to regulation is necessary, one that acknowledges the differences in risk between nicotine products and prioritises harm reduction.
